Columbia Labs Crinone NDA approval, launch anticipated in second quarter, firm tells investors.
Executive Summary
COLUMBIA LABS CRINONE NDA APPROVAL ANTICIPATED IN SECOND QUARTER, Chairman William Bologna told investors Jan. 23 at the American Stock Exchange Health Care Conference in New York. "This product has been given priority rating at the FDA and we have a six-month review" schedule, he said. "We expect approval in the U.S. next quarter." The NDA for Crinone (progesterone) for use in assisted reproductive technology procedures was filed on Nov. 13 and subsequently granted priority review status. The user fee deadline is May 13.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth